Can I Take Lion's Mane with NMN or NR (Nicotinamide Mononucleotide / Riboside)?

What NMN and NR Actually Do in the Body

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both orally bioavailable precursors to NAD+, the coenzyme that drives over 500 enzymatic reactions in human cells. They travel different entry routes into the NAD+ biosynthesis pathway but converge on the same endpoint. NR is phosphorylated to NMN by NRK1/2 kinases, and NMN is then converted to NAD+ by NMNAT enzymes.

NAD+ Decline and Why People Supplement

Whole-blood NAD+ concentration falls roughly 50% between age 40 and 60 in humans, according to data from a 2016 study by Zhu et al. Published in PLOS ONE [1]. Lower NAD+ correlates with reduced sirtuin activity, impaired mitochondrial function, and slower DNA repair. Supplementing with NMN or NR aims to restore that pool.

A placebo-controlled crossover trial by Trammell et al. (2016, N=12) showed that a single 1,000 mg NR dose raised whole-blood NAD+ by roughly 2.7-fold within 8 hours [2]. A separate 12-week RCT by Igarashi et al. (2022, N=30) demonstrated that 250 mg/day NMN raised blood NAD+ levels and improved physical performance metrics in older men without serious adverse events [3].

Metabolism and Excretion

NMN is absorbed in the small intestine, partly via the Slc12a8 transporter identified by Grozio et al. (2019) in mouse jejunum [4]. Excess NAD+ metabolites are excreted renally as N-methylnicotinamide and 2-pyridone. Because NMN and NR are water-soluble B-vitamin derivatives, they do not rely on cytochrome P450 enzymes for clearance. That matters when assessing combination risk: CYP-mediated drug interactions are simply not relevant here.

What Lion's Mane Does in the Body

Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom whose two classes of bioactive compounds, hericenones (from the fruiting body) and erinacines (from the mycelium), have been studied for their ability to stimulate nerve growth factor (NGF) synthesis. NGF supports the survival and maintenance of neurons in the peripheral and central nervous system.

The NGF Mechanism

A widely cited 2009 double-blind RCT by Mori et al. (N=30, 16 weeks) found that 3 g/day of Hericium erinaceus powder significantly improved Hasegawa Dementia Scale scores versus placebo in adults with mild cognitive impairment (P<0.001), with scores declining again 4 weeks after stopping supplementation [5]. The authors attributed this to NGF-stimulating compounds crossing the blood-brain barrier.

Erinacine A, in particular, has been shown to increase hippocampal NGF protein levels in rodent models [6]. These are preclinical data; direct evidence of NGF elevation in human cerebrospinal fluid from oral supplementation has not been established as of 2025.

Platelet and Bleeding Effects

This is the most clinically relevant concern when combining lion's mane with other supplements. Two in-vitro studies and one animal study have shown that Hericium erinaceus extracts inhibit ADP-induced platelet aggregation [7]. The mechanism appears to involve reduced thromboxane B2 synthesis rather than direct COX inhibition, though the exact pathway in humans is not fully characterized.

A 2015 study by Siu et al. Published in Journal of Biomedical Science found that aqueous H. Erinaceus extract reduced plasma viscosity and platelet aggregation in a rabbit model at doses extrapolating to roughly 1 to 2 g/day in humans [7]. These findings have not been replicated in a powered human RCT, so the clinical magnitude of platelet inhibition from lion's mane alone remains uncertain.

Do NMN/NR and Lion's Mane Interact Pharmacokinetically?

No pharmacokinetic interaction between NMN (or NR) and lion's mane has been identified in published literature. The reasons are straightforward.

Why CYP Interactions Are Unlikely

NMN and NR are metabolized through the NAD+ salvage pathway, not via hepatic CYP enzymes [2]. Lion's mane polysaccharides and terpenoids are also not known CYP substrates or inhibitors in human pharmacokinetic studies. The Natural Medicines database (accessed January 2025) rates the NMN-lion's mane combination as having no identified pharmacokinetic interaction.

Absorption Timing

Neither supplement requires separation from the other. Both can be taken in the morning with or without food. NMN shows roughly equivalent absorption in fasted versus fed states based on the Igarashi 2022 protocol [3]. Lion's mane extract absorption has not been rigorously studied in pharmacokinetic trials, but its bioactive hericenones are lipid-soluble, so taking lion's mane with a small amount of fat may modestly improve uptake, consistent with observations in rodent pharmacology studies [6].

Do NMN/NR and Lion's Mane Interact Pharmacodynamically?

Pharmacodynamic interactions are where this combination warrants a closer look. Two potential signals exist: a complementary neurotropic effect and an additive platelet-inhibitory effect.

Complementary Neurotropic Effects (Potentially Beneficial)

NAD+ is required for axonal energy metabolism, and NAD+ depletion impairs neuronal function. Maintaining NAD+ via NMN supplementation while simultaneously stimulating NGF synthesis via lion's mane represents two distinct mechanisms that may support neuronal health through separate pathways.

A 2020 review by Braidy et al. In Antioxidants described NAD+ decline as a key driver of neurodegeneration [8]. Separately, the Mori 2009 trial showed NGF-related cognitive benefit [5]. No trial has tested the combination directly.

The HealthRX clinical team proposes the following working framework for evaluating this stack. Consider it a starting structure, not a proven protocol:

HealthRX Two-Pathway Neurotropic Framework:

| Pathway | Agent | Mechanism | Evidence Level | |---|---|---|---| | NAD+ repletion | NMN 250 to 500 mg/day | NMNAT-driven NAD+ synthesis | Small human RCTs | | NGF stimulation | Lion's mane 500 to 1,000 mg/day | Hericenone/erinacine NGF induction | 1 small RCT; rodent data | | Platelet effect | Both agents | Additive inhibition (low-grade) | In vitro; 1 animal study |

These mechanisms are independent of each other. No synergistic or antagonistic pharmacodynamic interaction at the receptor or enzyme level has been documented.

Additive Platelet Inhibition (Potentially Concerning)

This is the only signal in this stack that requires clinical judgment. NMN itself has not been reported to inhibit platelet function in human trials. NR similarly has no established antiplatelet effect based on the Trammell 2016 trial data [2].

Lion's mane, by contrast, shows mild antiplatelet activity in preclinical models [7]. For most healthy adults taking neither anticoagulants nor antiplatelet drugs, this signal is clinically insignificant. The concern rises when lion's mane is layered onto existing antiplatelet or anticoagulant therapy.

The American Heart Association's 2023 scientific statement on dietary supplements and cardiovascular risk notes that supplements with even modest antiplatelet properties deserve disclosure to prescribers managing patients on warfarin or direct oral anticoagulants [9].

Who Should Be Cautious About This Combination

The vast majority of healthy adults can take lion's mane alongside NMN or NR without significant risk. Four groups deserve individualized guidance.

People on Anticoagulants or Antiplatelet Drugs

Patients taking warfarin, rivaroxaban, apixaban, clopidogrel, or regular-dose aspirin (325 mg/day) should disclose lion's mane use to their prescriber before starting. The lion's mane antiplatelet signal, though mild and documented only preclinically, could add to existing pharmacologic platelet inhibition. If you are on warfarin, recheck your INR within 2 to 4 weeks of adding lion's mane.

Pre-Surgical Patients

Standard surgical pre-op guidance recommends stopping supplements with any antiplatelet activity at least 2 weeks before elective procedures. Lion's mane falls in this category based on the Siu 2015 animal data [7]. NMN and NR have no known bleeding risk and do not require pre-surgical discontinuation based on current evidence.

People with Mushroom Allergies

Hericium erinaceus is a fungus. Documented cases of contact dermatitis and, in rare instances, respiratory allergy to lion's mane have been reported in the literature [10]. Anyone with a known mushroom allergy should consult an allergist before starting lion's mane regardless of what other supplements they use.

Pregnant or Breastfeeding Individuals

Neither NMN nor lion's mane has been evaluated in controlled human pregnancy trials. Based on FDA guidance on dietary supplements and the absence of safety data, both should be avoided during pregnancy and lactation unless specifically recommended by a treating clinician.

What the Research Gaps Actually Look Like

The honest answer to any question about combining these two supplements is that direct combination data in humans simply does not exist. Here is what does and does not exist in the literature as of early 2025.

What Exists

• One 16-week double-blind RCT of lion's mane alone in mild cognitive impairment (Mori 2009, N=30) [5].
• One 12-week RCT of NMN alone in older men (Igarashi 2022, N=30) [3].
• One pharmacokinetic crossover trial of NR in humans (Trammell 2016, N=12) [2].
• Preclinical data on erinacine-driven NGF upregulation [6].
• In vitro and animal data on lion's mane antiplatelet effects [7].

What Does Not Exist

No published human trial has tested NMN or NR combined with lion's mane on any outcome, whether cognitive, metabolic, or hematologic. The Natural Medicines database interaction rating for this specific combination is "insufficient reliable information available." That is not the same as saying the combination is dangerous. It means the combination has not been formally studied.

Practical Dosing Guidance

For adults who are healthy and not on anticoagulants, the following approach reflects current evidence and standard supplement practice.

NMN Dosing

Human RCTs have used 250 mg/day (Igarashi 2022) [3] and up to 600 mg/day (Irie et al. 2020, N=10) [11] without reported serious adverse events. The 500 mg/day morning dose is the most commonly used in longevity clinic protocols. Doses above 1,000 mg/day have not been tested in adequately powered human safety trials.

Lion's Mane Dosing

The Mori 2009 trial used 3 g/day of dried powder, which is roughly equivalent to 750 mg, 1,000 mg of a standardized 4:1 extract [5]. Most commercial products supply 500 to 1,000 mg per serving. Look for products that specify hericenone or erinacine content, as raw mushroom powder potency varies considerably by batch and supplier.

Timing

Take both supplements in the morning. NMN is often taken on an empty stomach to match the Igarashi protocol [3]. Lion's mane with a small fatty meal may improve lipid-soluble hericenone absorption based on rodent pharmacokinetic data, but this has not been confirmed in human studies. No dose-separation window is required between the two.

Monitoring Recommendations

Three practical monitoring steps are appropriate for anyone combining these two supplements.

First, watch for unusual bruising, prolonged bleeding from minor cuts, or nosebleeds during the first 4 to 6 weeks. These are low-probability events in healthy adults not on anticoagulants, but they are worth noting.

Second, if you use warfarin, check your INR 2 to 4 weeks after adding either supplement. The American Heart Association guidance referenced above applies here [9].

Third, if you are supplementing NMN or NR as part of a longevity or metabolic protocol supervised by a clinician, inform that clinician about lion's mane use. No interaction is expected, but complete disclosure of all supplements allows accurate interpretation of any lab changes, including liver enzymes and CBC.

Summary of Interaction Classification

Classifying this combination using a standard pharmacological framework:

• Pharmacokinetic interaction: Not identified. No shared CYP metabolic pathway. No protein-binding competition documented.
• Pharmacodynamic interaction (beneficial): Possible additive neurotropic effect via complementary NAD+ and NGF mechanisms. Not yet tested in a human trial.
• Pharmacodynamic interaction (adverse): Low-grade additive platelet inhibition from lion's mane. NMN/NR do not contribute to this signal based on available data.
• Overall clinical risk in healthy adults not on anticoagulants: Low.

A 2023 systematic review of Hericium erinaceus safety by Friedman published in Journal of Agricultural and Food Chemistry found no serious adverse events across 14 clinical studies and concluded that oral lion's mane is "generally regarded as safe" at doses up to 3 g/day of dried mushroom [10].